Skip to main content

Pathology tests database

Back to Clinical Biochemistry

C-Peptide

Clinical Biochemistry

Sample and container requirements

EDTA Plasma

Minimum volume required

1mL blood

Special requirements

Sample should be spun within 24hrs. Plasma should be stored frozen. Stable at RT for 24 hours unspun, 7 days spun. Store at -20C.

Patient preparation

If using for investigation of hypoglycaemia, patient must be hypoglycaemic at time of sampling (Venous glucose: <3.1 mmol/L).

Sample viability

Turnaround time

7 days

Reference range

#VALUE!

Clinical guidance

Analysis of urinary c-peptide is also available, for specimen requirements see c-peptide (urine). Determination of the C-peptide is an additional option to monitor average β-cell insulin secretion. C-peptide is used as a test of β-cell function in a variety of conditions including type 1 diabetes, and to aid in the differential diagnosis of hypoglycemia, and surreptitious insulin self-administration. A low C-peptide level is expected if the insulin secretion is diminished as in insulin-dependent diabetes (type 1 diabetes, latent autoimmune diabetes of adults (LADA)). Elevated C-peptide levels may be found when β-cell activity is increased as in hyperinsulinism, insulin resistance (with high blood glucose) and insulinomas (with low blood glucose). Inappropriately raised plasma insulin concentrations in the presence of low or suppressed plasma C-peptide will identify patients with exogenous insulin administration. Suppressed plasma insulin and C-peptide concentrations in the presence of hypoglycaemia can be caused by chronic kidney disease, liver disease, alcohol and drugs. C-peptide is cleared by the kidneys, therefore impairment in renal function can make C-peptide results difficult to interpret.

Notes

Images to go here

This information was last updated on 19 August 2026